The pharmaceutical sector entered a new regulatory epoch on April 2, 2026. President Trump’s Section 232 proclamation imposed tariffs of up to 100% on patented pharmaceutical imports and active pharmaceutical ingredients (APIs), citing national security grounds under the Trade Expansion Act of 1962. The clock is now running. Seventeen named companies face a July 31, 2026 compliance deadline — 120 days from proclamation. All other covered companies have until September 29, 2026. There is no extension mechanism built into the proclamation.
This is not a future risk to be modeled. It is an operational decision already overdue at the board level.
What the Proclamation Actually Does
The 100% tariff applies to patented pharmaceuticals listed in the FDA’s Orange Book (approved drugs) and Purple Book (licensed biologics), along with their associated APIs and key starting materials. Generics are explicitly exempt — the tariff is targeted at branded, patent-protected products where the United States has the greatest dependency on foreign manufacture.
The rate structure is not flat. It operates as a floating levy: where a product already carries a non-zero Most-Favored-Nation (MFN) tariff rate, the Section 232 tariff is reduced so that the combined duty reaches exactly 100%. If an existing MFN rate exceeds 100%, only that rate applies. For imports from allied nations — the EU, Japan, South Korea, and Switzerland/Liechtenstein — the Section 232 component is set at 15%, bringing effective rates significantly below 100% for those supply chains. The UK faces a 10% Section 232 component.
There is an exit ramp. Companies that submit qualifying onshoring plans to the Secretary of Commerce — and that have entered into Most-Favored-Nation pharmaceutical pricing agreements — are eligible for a tariff rate of zero until January 20, 2029. This is the central strategic fork every pharma board now faces: absorb the tariff, restructure the supply chain, or negotiate the onshoring pathway.
The Board-Level Decision Window Is Compressed
The Secretaries of Commerce and HHS are directed by the proclamation to publish criteria for qualifying onshoring plans in the Federal Register. Those criteria are not yet finalized. This creates a structural problem: companies cannot design compliant onshoring plans until the criteria are published, yet the tariff clock is already running. For the 17 Annex III companies, the practical planning window is 105 days or fewer by today’s date.
Boards need to operate on three parallel tracks simultaneously. The first is exposure classification: every product in the company’s portfolio must be mapped against the Orange Book and Purple Book, with its current country of manufacture and API sourcing identified. Products with dual-source supply chains from exempt jurisdictions (EU, Japan, Korea, Switzerland) may already be positioned to navigate the 15% pathway rather than 100%. That assessment cannot wait for outside counsel.
The second track is financial modeling. A 100% tariff on a patented drug with 60% of its API sourced from China does not produce a 100% cost increase — it produces a cost structure that eliminates margin entirely on affected SKUs. CFOs need to run scenario models now against current gross margin by product, not wait for the Federal Register publication.
The third track is the onshoring negotiation itself. The Secretary of Commerce will approve, monitor, and enforce onshoring plans. Companies with existing U.S. manufacturing footprints, announced capacity investments, or credible capital commitments are better positioned to submit qualifying plans. Boards without an existing domestic manufacturing strategy are not starting from zero — they are starting from behind.
What This Means for Non-Pharma Boards
The Section 232 pharmaceutical action is not isolated. It is the fourth major Section 232 action of this administration, following steel, aluminum, and semiconductors. The pattern is now established: the national security framing allows tariffs that bypass traditional WTO dispute mechanisms and do not require Congressional authorization. Any board with significant exposure to patented, import-dependent product categories — medical devices, specialty chemicals, advanced materials — should treat this proclamation as a template for what their sector faces, not as a pharma-specific anomaly.
The 15% carve-out for allied nation supply chains also signals something important about the administration’s structural intent. Companies that have concentrated supply chains in China without allied-nation diversification have materially higher tariff exposure than companies that maintained geographic spread. The diversification decisions made between 2020 and 2024 are now pricing themselves into earnings.
The Governance Imperative
Pharmaceutical boards that have not yet convened a dedicated session on tariff exposure classification, onshoring pathway eligibility, and financial scenario modeling are in breach of the duty of care standard that applies to material financial risk. The July 31 deadline is not a regulatory milestone — it is a fiduciary deadline. Directors of Annex III companies who cannot document that their boards reviewed and acted on tariff exposure before July 31 will face significant liability risk if subsequent shareholder challenges arise.
The onshoring pathway is available. The allied-nation pricing pathway is available. The zero-tariff option remains open until January 20, 2029. None of those options are available to boards that have not yet started the classification and modeling work.
The decision window is 105 days. That is not enough time to build a domestic manufacturing facility. It is enough time to negotiate supply chain shifts, file onshoring commitments, and position the company for the reduced tariff track — but only if the work begins immediately.